Exatecan
![]() | |
| Names | |
|---|---|
| IUPAC names
(1S,9S)-1-Amino-9-ethyl-5-fluoro-1,2,3,9,12,15-hexahydro-9-hydroxy-4-methyl-10H,13H-benzo(de)pyrano(3',4':6,7) indolizino(1,2-b)quinoline-10,13-dione | |
| Identifiers | |
| 171335-80-1 | |
| 3D model (Jmol) | Interactive image Interactive image |
| ChEMBL | ChEMBL1614650 |
| ChemSpider | 133194 |
| PubChem | 151115 |
| UNII | OC71PP0F89 |
| |
| |
| Properties | |
| C24H22FN3O4 | |
| Molar mass | 435.447583 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| | |
| Infobox references | |
Exatecan is a drug which is an analogue of camptothecin with antineoplastic activity.[1]
Synthesis

Exatecan synthesis[2]
References
- ↑ Abou-Alfa, GK; Letourneau, R; Harker, G; Modiano, M; Hurwitz, H; Tchekmedyian, NS; Feit, K; Ackerman, J; De Jager, RL; Eckhardt, SG; O'Reilly, EM (20 September 2006). "Randomized Phase III Study of Exatecan and Gemcitabine Compared with Gemcitabine Alone in Untreated Advanced Pancreatic Cancer" (PDF). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 24 (27): 4441–7. doi:10.1200/JCO.2006.07.0201. PMID 16983112. Retrieved 15 July 2016.
- ↑ H. Terasawa, A. Ejima, S. Ohsuki, K. Uoto, U.S. Patent 5,834,476 (1998).
This article is issued from Wikipedia - version of the 7/18/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
